It evaluates the risk of breast and ovarian cancers by considering data on multiple family members, ages at diagnosis, and the presence of specific genetic mutations, including BRCA1, BRCA2, TP53, and others (28). This evidence concerns the gene BRCA2 and ovarian cancer.